BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 28, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
BioWorld Science, Neurology/psychiatric RSS Feed RSS

Brain, syringe hovering over hands
Neurology/psychiatric

Stem cell-derived factor has potential in anti-NMDAR encephalitis

Feb. 16, 2026
No Comments
Researchers have explored the effects of human umbilical cord mesenchymal stem cells (hUC-MSCs) on cognitive recovery in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, a rare, neuronal antibody-mediated disorder characterized by neuropsychiatric symptoms and impaired cognitive function. hUC-MSCs have previously shown immunomodulatory and anti-inflammatory properties.
Read More
Neurology/psychiatric

Nanjing Anji Biotechnology synthesizes new OGDH inhibitors

Feb. 13, 2026
Nanjing Anji Biotechnology Co. Ltd. has discovered 2-oxoglutarate dehydrogenase, mitochondrial (OGDH; OGDC-E1) inhibitors. They are reported to be useful for the treatment of schizophrenia, liver fibrosis, liver cancer, diabetic nephropathy, heart failure, Alzheimer’s, Parkinson’s and Huntington’s disease, among others.
Read More
Illustration of head with maze that is missing parts
Neurology/psychiatric

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

Feb. 13, 2026
No Comments
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play a crucial role. Researchers from Augusta University in the U.S. hypothesized that inhibiting the NLRP3 inflammasome with MCC-950 may improve cognitive decline and cerebral blood flow in a murine model of VCID.
Read More
Lab glassware and scientist
Neurology/psychiatric

Nxera announces partner program updates

Feb. 13, 2026
No Comments
Nxera Pharma Co. Ltd. has announced the achievement of an early development milestone by Centessa Pharmaceuticals plc for ORX-489, triggering a payment to Nxera under the companies’ research collaboration.
Read More
Illustration of normal muscle compared to muscle atrophy in cancer cachexia or anorexia
Cancer

Tumor, immune and neural cells are involved in cancer cachexia

Feb. 12, 2026
By Mar de Miguel
No Comments
A circuit formed by tumor, immune and nervous systems triggers cancer cachexia and anorexia, the excessive loss of weight, muscle and fat experienced in some cancer types. A new study is the first showing these three actors of a triangle interaction that initiates and feeds the process.
Read More
Neurology/psychiatric

Yuhan patents new TREM2 agonists

Feb. 12, 2026
Yuhan Corp. has disclosed triggering receptor expressed on myeloid cells 2 (TREM2) agonists described as potentially useful for the treatment of neurological disorders.
Read More
Neurology/psychiatric

Sundance Biosciences synthesizes new TYK2 inhibitors

Feb. 12, 2026
Sundance Biosciences Inc. has discovered non-receptor tyrosine-protein kinase TYK2 inhibitors potentially useful for the treatment of multiple sclerosis.
Read More
Optogenetics illustration
Ocular

New models, gene therapy approach for ocular phenotype of Friedreich’s ataxia

Feb. 12, 2026
No Comments
Friedreich’s ataxia (FA), the most common form of hereditary ataxia, is an autosomal recessive neurodegenerative disorder affecting multiple organ systems, and causing cardiomyopathy, scoliosis, muscle weakness, speech impairment and other systemic issues.
Read More
Illustration of brain and antibodies
Neurology/psychiatric

VST Bio’s VB-001 is neuroprotector after stroke

Feb. 12, 2026
No Comments
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal antibody that targets syndecan 2 (SDC2) and is also known as VST-002.
Read More
Neurology/psychiatric

Genome-wide CRISPRi screen provides insights into tau proteostasis

Feb. 12, 2026
No Comments
Tau is an intrinsically disordered protein that regulates the stability and dynamics of microtubules in physiological conditions. Recent work has revealed the involvement of tau in various neuronal processes. Researchers from the University of California and collaborators aimed to systematically investigate the cellular factors that control the accumulation of tau aggregates in human neurons.
Read More
Previous 1 2 … 12 13 14 15 16 17 18 19 20 … 2804 2805 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 27, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 26, 2026
  • Microscopy of a cross-section of mouse skin containing melanoma tumors

    Researchers identify innate immune barrier against melanoma

    BioWorld
    Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
  • In the clinic for May 26, 2026

    BioWorld
    Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
  • Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers

    BioWorld Science
    Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing